Navigation Links
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
Date:6/26/2009

OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").

The Private Placement took place through a bookbuilding process and was managed by Carnegie ASA and DnB NOR Markets as joint-lead managers and joint bookrunners. The Private Placement, which represents approximately 80% of the current outstanding share capital, was well oversubscribed at the issue price and was supported by existing life science and institutional investors, including NeoMed Management and MVM Life Science Partners, as well as new institutional investors.

The net proceeds to the Company from the Private Placement will provide financial resources to achieve key clinical data on its products in development, and optimise its commercial strategy. More specifically, the Company intends to use the net proceeds to:

    i)  Obtain randomised data from clinical studies for lead products
         a. Complete first part of a Phase II/III registration study for
            elacytarabine in leukaemia (AML)
         b. Complete a randomised Phase II study with IV CP-4126 in
            pancreatic cancer
         c. Complete Phase I study for Oral CP-4126 in various solid cancers
    ii)  Achieve pre-clinical proof of concept for CP-4200
    iii) Place the company in a position of strength from which to negotiate
         appropriate partnership agreements as well as for general corporate
         purposes

Completion of the Private Placement is conditional upon approval by the Company's Extraordinary General Meeting to be held on or about 15 July 2009 (the "EGM"). Shareholders representing more than the required two thirds of the shares
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... 2013  HealthSparq, a trusted provider of healthcare ... regional health plans, will debut a new benchmark ... Institute 2013 conference on June 13.  The presentation ... health insurance companies across the country are thinking ... demands for increased healthcare transparency. ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 On average, ... costs over one billion dollars. Despite this investment, less ... stakes this high, is your clinical trial design optimally ... the best outcomes? , Dr. Frederic Sax, Global Head ... discuss the use of data, information and technology in ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... ASHBURN, Va., March 31 - Innocoll, Inc. announced that ... 510k application for its CollaRx(TM) Lidocaine Sponge for the ... each year 13 million patients worldwide suffer from chronic ... etc.) 35 percent of all chronic wounds do ...
... Make Soyfoods Even HealthierST. LOUIS, March 31 Recent ... soy to be beneficial to the diet. And, the ... food products such as soyfoods even healthier. These findings ... Attitude Survey - sponsored by the United Soybean ...
... manufacturing, Selexis is now offering a portfolio of ... added characterization servicesGENEVA, March 31 Selexis SA, ... for the rapid development of high-performance stable production ... on the biosimilar market segment. Under the ...
Cached Biology Technology:Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Selexis Launches Biosimilar Cell Line Development Program 2
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
(Date:5/16/2013)... YORK , May 16, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Forecast & Opportunities, 2018 ... protection and old security practises such as ... the growth of biometric technologies in last ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... is not as well known as other, more widely used ... fly, nematode or mouse. But University of Illinois cell and ... it turns out, the tiny, seemingly cross-eyed flatworm is an ... eggs and sperm in all sexually reproducing species. , ...
... has puzzled scientists for decades, MIT and Harvard researchers ... of vitamin B12-the only vitamin synthesized exclusively by microorganisms. ... is essential for human health. Four Nobel Prizes have ... fragment of the molecule remained an enigma-until now. ...
... Cincinnati (UC) environmental health researchers say a therapy commonly ... the body may also improve muscle functions associated with ... Led by Amit Bhattacharya, PhD, the UC team found ... a 19 percent improvement in their ability to perform ...
Cached Biology News:Study of planarians offers insight into germ cell development 2MIT biologists solve vitamin puzzle 2MIT biologists solve vitamin puzzle 3Lead-'scrubbing' drug may also improve muscle function in lead-exposed children 2